ASCO - Gastrointestinal Cancers Symposium Orlando (FL), 25-27 January 2008 First-line Irinotecan, Oxaliplatin and Infusional 5FU/LV (FOLFOXIRI) in combination.
Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer KRAS Status in Response to Cetuximab Retrospective.
Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma Future Directions: Opportunities for Targeting B-RAF and Other Targets in Melanoma.
Optimizing the use of trabectedin in the daily clinical practice in ASTS Axel Le Cesne, MD.
Emerging Concepts in the Management of Skin Cancer Perspectives From the 2015 Oncology Meeting Targeted Therapy for Metastatic Melanoma Keith T. Flaherty,
Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma David F. McDermott, MD Clinical Director, Biologic Therapy Program Beth Israel Deaconess.
Novel Targets and Therapies for GI Malignancies: What does the future hold? David H. Ilson, M.D., Ph.D. GI Oncology Service Memorial Sloan-Kettering Cancer.
1 Division of Oncology Drug Products Presentation NDA 21-649 Genasense (Oblimersen) for metastatic melanoma ODAC May 3, 2004.
1 New Developments in the Management of Advanced Breast Cancer Supported by an educational grant from Roche Laboratories Including Updates from ASCO 2007.
A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized unresectable pancreatic.